PolarityBio to Present Phase 3 SkinTE Data at SAWC Fall 2026
SALT LAKE CITY — September 29, 2026 PolarityBio announced that results from its pivotal Phase 3 COVER DFUS II...
RMAT
Advertisement
uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
Ocugen Gains Provisional Approval for OCU400 in The Bahamas
MALVERN, Pa. — September 25, 2026 Ocugen Inc. announced that its investigational modifier gene therapy OCU400 has received provisional...
Beacon Therapeutics Reports Positive VISTA Data for Laru-zova
LONDON and CAMBRIDGE, Mass September 21, 2026 — Beacon Therapeutics announced positive topline results from the pivotal VISTA trial...
PolarityBio Gains FDA Priority Review for SkinTE in DFUs
SALT LAKE CITY, Utah — September 15, 2026 PolarityBio announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
Tenaya Therapeutics Gains RMAT Designation for TN-401
SOUTH SAN FRANCISCO, Calif. — September 14, 2026 Tenaya Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
Artiva Biotherapeutics Advances AlloNK Toward Phase 3 in RA
SAN DIEGO, California — September 8, 2026 Artiva Biotherapeutics, Inc. announced planned clinical data disclosures and development milestones for...
Fate Therapeutics Advances FT819 in Lupus Nephritis
San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program
Warren, New Jersey, August 12, 2026 PTC Therapeutics announced that it was selected as the winning bidder to acquire...
Pacira BioSciences Publishes Two-Year Phase 1 PCRX-201 Knee OA Data
BRISBANE, Calif., August 6, 2026 Pacira BioSciences announced the publication of positive two-year Phase 1 clinical trial results for...
Advertisement
